Nebenwirkungen · Ebymect
Ebymect 5 mg/850 mg film-coated tablets Ebymect 5 mg/1,000 mg film-coated tablets · Abschnitt 4.8 · PDF-Seite 15
HOS-224613 · Präparat HOS-217324
Urinary tract infections In the 13-study safety pool, urinary tract infections were more frequently reported for dapagliflozin compared with placebo (4.7% versus 3.5%, respectively; see section 4.4). Most infections were mild to moderate, and subjects responded to an initial course of standard treatment and rarely resulted in discontinuation from dapagliflozin treatment. These infections were more frequent in females, and subjects with a prior history were more likely to have a recurrent infection.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-03-13T16:17:00Z · SHA-256 caa90fe123bd26ff6eae05f7cbf5eaec9b795769b9a4b1be4fc8632ea0cf36ca · Passage f089686517086b28a3455c6e5a529b22260eab729536344e3ad7f661537d1e10 · Zeichen 13967–14470 im Abschnitt